We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Groupon, Inc. (GRPN) - free report >>
Smartsheet (SMAR) - free report >>
Renalytix AI PLC Sponsored ADR (RNLX) - free report >>
Image: Bigstock
New Strong Buy Stocks for October 26th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Groupon, Inc. (GRPN - Free Report) : This marketplace which connects consumers to merchants has seen the Zacks Consensus Estimate for its current year earnings increasing 13.9% over the last 60 days.
Groupon, Inc. Price and Consensus
Groupon, Inc. price-consensus-chart | Groupon, Inc. Quote
Nurix Therapeutics, Inc. (NRIX - Free Report) : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 18.1% over the last 60 days.
Nurix Therapeutics, Inc. Price and Consensus
Nurix Therapeutics, Inc. price-consensus-chart | Nurix Therapeutics, Inc. Quote
Renalytix Plc (RNLX - Free Report) : This kidney disease diagnostic solutions company has seen the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.
Renalytix AI PLC Sponsored ADR Price and Consensus
Renalytix AI PLC Sponsored ADR price-consensus-chart | Renalytix AI PLC Sponsored ADR Quote
AbCellera Biologics Inc. (ABCL - Free Report) : This antibody drug development platform provider has seen the Zacks Consensus Estimate for its current year earnings increasing 7.3% over the last 60 days.
AbCellera Biologics Inc. Price and Consensus
AbCellera Biologics Inc. price-consensus-chart | AbCellera Biologics Inc. Quote
Smartsheet Inc. (SMAR - Free Report) : This work management solutions provider has seen the Zacks Consensus Estimate for its current year earnings increasing 31.7% over the last 60 days.
Smartsheet Price and Consensus
Smartsheet price-consensus-chart | Smartsheet Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.